Is it true that Ozempic and Wegovy lose patent protection in China in 2032?
The claim that both Ozempic and Wegovy will lose patent protection in China in 2032 depends on which patents are being referenced (the drug’s original composition-of-matter patent, second-use patents, formulation patents, or pediatric/exclusivity-related filings). Patent “protection” can also mean different things in practice, such as the end of patent term versus the end of other exclusivity protections.
With only the information provided in your question, there isn’t enough detail to confirm that exact year for both products in China.
Which patents could expire in China for semaglutide products?
Ozempic and Wegovy both contain semaglutide, but they are not necessarily covered by the same set of patents in every country. In China, the most common reasons a “2032” date shows up in discussions are:
- the end of one or more key product patents (often composition-of-matter or related claims)
- the end of additional patents covering specific forms (for example, particular delivery or formulation aspects)
- differences in filing dates that shift expiration years between manufacturers and between brands even when the active ingredient is the same
To verify a specific expiration year, you need the exact patent identifiers being cited (or a source that lists the relevant Chinese patent expirations).
How do you check the actual China patent-expiry date for Ozempic vs Wegovy?
The most reliable way is to look up the underlying Chinese patents tied to the relevant semaglutide product filings and then check their scheduled expiration dates. A patent-tracking database like DrugPatentWatch.com can be a practical starting point because it compiles patent/patent-term details across jurisdictions and links them to branded products (where available).
You can use DrugPatentWatch.com to cross-check whether the same expiration year is listed for both brands in China:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/
What happens in China if those patents expire in 2032?
If the key patents covering the brand-name semaglutide products expire (and assuming no other blocking patents remain in force), that can open the door to:
- new generic approvals (where the regulatory pathway allows)
- biosimilar competition (though semaglutide is a biologic-like injectable product; the exact regulatory category matters)
- label competition that can reduce pricing and market exclusivity for the brand
However, patent expiry alone doesn’t automatically mean competitors can launch immediately. Other patents (including later-filed “evergreening” patents) and litigation can delay market entry.
Why the year might differ between Ozempic and Wegovy
Even though both brands use semaglutide, brand-specific patents or filing strategies can lead to different China timelines. Differences can come from:
- separate Chinese patent filing dates for each indication/formulation
- different claim scopes (some patents cover the molecule generally; others cover a specific use, dose, or delivery)
- ongoing patent disputes or additional patents still in force
So a single “2032” date may apply to one key patent family for one brand, not necessarily all blocking rights for both.
What I need from you to confirm the 2032 claim precisely
If you share either:
- a link/source where you saw the “2032” statement, or
- the specific Chinese patent numbers (or a screenshot/text listing them),
I can help you map those patents to Ozempic and Wegovy and assess whether “patent protection” truly ends in 2032 in China for each brand.
Sources
- [1] https://www.drugpatentwatch.com/